Search Result

Results for "

p38alpha

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) Autophagy (31) Bcl-2 Family (1) Casein Kinase (11) Caspase (1) CDK (1) Cholinesterase (ChE) (2) Discoidin Domain Receptor (1) Drug Isomer (1) EGFR (1) Epigenetic Reader Domain (1) ERK (2) Interleukin Related (1) Isotope-Labeled Compounds (1) JAK (1) JNK (4) MAP3K (1) MAPKAPK2 (MK2) (3) MDM-2/p53 (1) NF-κB (1) Organoid (4) p38 MAPK (105) Parasite (1) Phosphatase (1) PROTACs (4) Raf (2) Reactive Oxygen Species (ROS) (2) Reference Standards (6) Small Interfering RNA (siRNA) (3) Src (5) Syk (1) TGF-β Receptor (5) Tie (2) TNF Receptor (3) VEGFR (1) Wee1 (1) Wnt (3) β-catenin (2)
By Research Areas:	Cancer (43) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (71) Metabolic Disease (5) Neurological Disease (11)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

113

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

p38-α MAPK-IN-1 1 Publications Verification	p38 MAPK Autophagy	Others
p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC₅₀ of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay .

JX401	p38 MAPK	Inflammation/Immunology
JX401 is a potent inhibitor of *p38alpha, containing a 4-benzylpiperidine motif. p38alpha* is hyperactive in inflammatory diseases, and various indications suggest that its inhibition would reverse inflammation. JX401 has the potential for the research of inflammation .

p38-α MAPK-IN-9	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-9 (Compound 25a) is a p38-α MAPK inhibitor (K_i: 0.057 nM). p38-α MAPK-IN-9 inhibits LPS (HY-D1056) induced TNFα production in hPBMCs (IC₅₀: 18 nM) .

p38-α MAPK-IN-4	p38 MAPK	Neurological Disease Inflammation/Immunology
p38-α MAPK-IN-4 (Compound 69) is a selective p38α MAPK inhibitor with an IC₅₀ of 1.5 µM. p38-α MAPK-IN-4 rapidly and strongly prevents the development of mechanical allodynia (MA) in vivo .

p38-α MAPK-IN-5	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-5 (compound 4e) is a potent *p38α* inhibitor with IC₅₀s of 0.1 nM, 0.2 nM, 944 nM, 4100 nM for p38α, p38 β, p38γ, p38δ, respectively. p38-α MAPK-IN-5 has anti-inflammatory effect. p38-α MAPK-IN-5 has the potential for asthma and chronic obstructive pulmonary disease (COPD) research .

p38-α MAPK-IN-10	p38 MAPK	Inflammation/Immunology
p38-α MAPK-IN-10 (Compound 6) is the inhibitor for *p38α* with an IC₅₀ of 4 nM .

p38-α MAPK-IN-7	p38 MAPK	Neurological Disease
p38-α MAPK-IN-7 (compound 4) is a *p38α-MAPK* inhibitor with an IC₅₀ value of 98.7 nM. p38-α MAPK-IN-7 protects neuronal cells from dexamethasone-induced ROS production .

p38-α MAPK-IN-6	p38 MAPK	Cancer
p38-α MAPK-IN-6 (compound 3a) is a *p38α* mitogen-activated protein kinase inhibitor .

p38-α MAPK-IN-8	Apoptosis Reactive Oxygen Species (ROS) p38 MAPK	Cancer
p38-α MAPK-IN-8 (Compound 13) is a lipophilic cationic derivative. p38-α MAPK-IN-8 is cytotoxic to various tumor cells, and can induce cell cycle arrest, apoptosis, increase reactive oxygen species (ROS) production, and induce mitochondrial membrane potential depolarization. The antitumor activity of p38-α MAPK-IN-8 may be related to p38α MAPK pathway, which can be used in the study of cancer .

p38α-IN-9	p38 MAPK MAPKAPK2 (MK2) CDK Wee1	Cancer
p38α-IN-9 (Compound 2015) is a *p38α* inhibitor and blocks p38α’s enzymatic activity with an IC₅₀ lower than 20 nM. p38α-IN-9 inhibits MK2 ^T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .

*ERK2/p38α MAPK-IN-1*	ERK p38 MAPK	Cancer
ERK2/p38α MAPK-IN-1 (Compound 1, In silico Hit-2) is a potent and selective ERK2 and p38α MAPK inhibitor, with an IC₅₀ of 82 μM for ERK2. ERK2/p38α MAPK-IN-1 binds to the allosteric site of ERK2 and p38α MAPK in distinct manners. ERK2/p38α MAPK-IN-1 can be used for the research of type 2 diabetes .

p38α inhibitor 1	p38 MAPK Autophagy	Inflammation/Immunology
p38α inhibitor 1 is a *p38α* inhibitor extracted from patent WO 2008076265 A1.

p38α inhibitor 3	p38 MAPK	Inflammation/Immunology
p38α inhibitor 3 (Comp G7) is a *p38α* inhibitor that blocks the effectiveness of myoblast differentiation .

p38α inhibitor 7	p38 MAPK	Inflammation/Immunology
p38α inhibitor 7 (compound 1) is an effective *p38α* inhibitor with oral efficacy and generally favorable pharmacokinetic properties .

p38α inhibitor 4	p38 MAPK	Cancer
p38α inhibitor 4 (compound 10) is a selective and allosteric *p38α* inhibitor with an IC₅₀ value of 1.2 μM. p38α inhibitor 4 exhibits no activity against p38β, p38γ, and p38δ .

p38α inhibitor 6	p38 MAPK Apoptosis Bcl-2 Family MDM-2/p53 Caspase	Cancer
p38α inhibitor 6 (compound 19) is a *p38α* inhibitor with the IC₅₀ of 0.68 μM. p38α inhibitor 6 induces cell apoptosis and arrests cell cycle at G0 and G2/M phase. p38α inhibitor 6 decreases the *TNF-α* concentration as well as increased the expression of tumor suppressor gene p53, Bax/BCL-2 ratio and caspase 3/7 .

p38α-MK2-IN-1	MAPKAPK2 (MK2) p38 MAPK	Inflammation/Immunology
p38α-MK2-IN-1 (Compound 36) is a *p38α-MK2* complex inhibitor (IC₅₀: 5 nM). p38α-MK2-IN-1 has a robust inflammation inhibitory effect and joint repair ability .

p38α inhibitor 8	p38 MAPK Casein Kinase	Inflammation/Immunology
p38α inhibitor 8 (Compound 1) exhibits inhibitory activity against p38α MAPK and CK1δ with IC₅₀ of 0.21 µM and 0.202 µM ^[1]>.

p38α inhibitor 2	p38 MAPK	Inflammation/Immunology
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC₅₀ of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC₅₀=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .

*BChE/p38-α MAPK-IN-1*	p38 MAPK Cholinesterase (ChE) Interleukin Related	Neurological Disease Inflammation/Immunology
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor of hBChE (IC₅₀ = 772 nM) and p38α MAPK (IC₅₀ = 191 nM). BChE/p38-α MAPK-IN-1 reduces the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-8, *TNF-α) in cells. BChE/p38-α MAPK-IN-1 improves Scopolamine (HY-N0296)-induced cognitive impairment, as well as alleviates LPS (HY-D1056)-induced spatial learning impairment and exerts anti-neuroinflammatory effects in mice. BChE/p38*-α MAPK-IN-1 can be used for the study of Alzheimer’s disease (AD) by targeting both cholinergic deficit and neuroinflammation .

p38α MAPK/CK1δ inhibitor-1	p38 MAPK Casein Kinase	Inflammation/Immunology
p38α MAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38α MAPK and CK1δ with IC₅₀s of 0.185 µM and 0.089 µM .

p38α inhibitor 5	p38 MAPK	Cancer
p38α inhibitor 5 (compound 1) is a PROTAC-type target protein ligand targeting p38 and can be used to synthesize NR-11c (HY-159798) .

R1487 Hydrochloride 1 Publications Verification	p38 MAPK Autophagy	Cancer
R1487 Hydrochloride is a highly potent and selective *p38α* inhibitor, with K_d values of 0.2 nM and 29 nM for p38α and p38β, respectively .

PF-05381941	MAP3K p38 MAPK	Inflammation/Immunology
PF-05381941 is a potent dual inhibitor of *TAK1/p38α, with IC₅₀*s of 156 and186 nM, respectively .

VX-702 3 Publications Verification	p38 MAPK Autophagy	Inflammation/Immunology
VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

SD 0006 SD-06	p38 MAPK Autophagy	Inflammation/Immunology
SD 0006 (SD-06) is an orally active, selective, ATP-competitive and potent diaryl pyrazole inhibitor of p38α MAP kinase, with an IC₅₀ of 110 nM for p38α .

AL 8697	p38 MAPK Autophagy	Inflammation/Immunology
AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC₅₀ of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC₅₀=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity .

p38 MAP Kinase Inhibitor IV	p38 MAPK	Inflammation/Immunology
p38 MAP Kinase Inhibitor IV is a highly specific ATP-competitive p38α MAPK inhibitor with IC₅₀s of 0.13 and 0.55 μM for p38α and p38β MAPK, respectively .

NR-7h	PROTACs p38 MAPK	Cancer
NR-7h is a potent and selective *p38α* and *p38β* degrader with DC₅₀ values of 24 nM and 27.2 nM for p38α in T47D, MB-MDA-231 cells, respectively .

Neflamapimod 5+ Cited Publications VX-745	p38 MAPK Autophagy	Inflammation/Immunology
Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of *p38α* inhibitor with an IC₅₀ for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.

BMS-582949	p38 MAPK	Inflammation/Immunology
BMS-582949 (compound 7k) is an orally active and highly selective p38α MAP kinase inhibitor, with IC₅₀ values of 13 nM for *p38α*, and 50 nM for cellular TNFα. BMS-582949 can be used for research on rheumatoid arthritis .

AZD 6703	p38 MAPK	Others
AZD 6703 is a p38α MAP kinase inhibitor with activity in inflammatory diseases.

ARRY-371797	Cholinesterase (ChE) p38 MAPK	Neurological Disease
ARRY-371797 is a potent and orally active p38α MAPK and BChE inhibitor with IC₅₀ values of 12.0, 0.13, ＞100 µM for p38α MAP, hBChE, hAChE, respectively. ARRY-371797 has the potential for the research of Alzheimer’s disease .

PH-797804 5+ Cited Publications	p38 MAPK Autophagy	Inflammation/Immunology Cancer
PH-797804 is a ATP-competitive, selective *p38α/p38β* inhibitor (IC₅₀=26 nM and K_i=5.8 nM for p38α; K_i=40 nM for p38β) and does not inhibit JNK2.

MW-150 MW01-18-150SRM	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

VX-702 (Standard)	Reference Standards p38 MAPK Autophagy	Inflammation/Immunology
VX-702 (Standard) is the analytical standard of VX-702. This product is intended for research and analytical applications. VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β .

NR-11c	PROTACs p38 MAPK	Cancer
NR-11c is a selective and potent p38α PROTAC degrader. NR-11c effectively degrades *p38α* in a variety of tumor cells. When administered intraperitoneally or intravenously to mice, NR-11c primarily acts in the liver. NR-11c can be used in cancer research. (Pink: p38α inhibitor 5 (HY-159799); Black: linker (HY-159800); Blue: VHL E3 ligase ligand (HY-112078)) .

JD123	p38 MAPK JNK	Cancer
JD123 inhibits JNK1 activity and the expression of cJun (1-135). JD123 is a ATP-competitive p38-γ MAPK inhibitor, but not effect to ERK1, ERK2, or p38-α, p38-β or p38-δ. .

Cyclocurcumin	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Cyclocurcumin is a potent *p38α* inhibitor. Cyclocurcumin shows antirheumatic, antivasoconstrictive and antioxidant activities .

Anti-inflammatory agent 33	p38 MAPK	Inflammation/Immunology
Anti-inflammatory agent 33 is a potent *p38α* inhibitor. Anti-inflammatory agent 33 inhibits NO production. Anti-inflammatory agent 33 inhibits LPS-induced iNOS, COX-2, p-p38α, p-MK2 protein expression. Anti-inflammatory agent 33 shows anti-inflammatory activity .

MW-150 hydrochloride MW01-18-150SRM hydrochloride	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 hydrochloride (MW01-18-150SRM hydrochloride) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

Acumapimod 1 Publications Verification BCT197	p38 MAPK Autophagy	Inflammation/Immunology
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC₅₀ of less than 1 μM for p38α.

SJFα	PROTACs p38 MAPK	Cancer
SJFα is a selective p38α PROTAC degrader with a DC₅₀ of 7.16 nM and D_max of 97.4%. SJFα is far less effective at degrading p38δ (DC₅₀ = 299 nM). SJFαcan be used for the research of cancer, such as breast cancer . (Structure Note: Pink: p38α ligand (HY-45124); Blue: VHL ligand (HY-125845))

MW-150 dihydrochloride dihydrate MW01-18-150SRM dihydrochloride dihydrate	p38 MAPK Autophagy	Neurological Disease Inflammation/Immunology
MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a K_i of 101 nM. MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia .

SB 239063 25+ Cited Publications	p38 MAPK Autophagy	Inflammation/Immunology
SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC₅₀ of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD .

SR-318	p38 MAPK TNF Receptor	Inflammation/Immunology Cancer
SR-318, a chemical probe, is a potent and highly selective p38 MAPK inhibitor with IC₅₀s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the *TNF-α* release in whole blood with an IC₅₀ of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .

Cat. No.	Product Name	Chemical Structure

HY-10405S

Pamapimod-d4

Pamapimod-d₄ (Ro4402257-d₄) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80776A

	*Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody* p38 (phospho T180 + Y182); p-p38 (phospho T180 + Y182); p38 (phospho T180/Y182); CSAID Binding Protein 1; CSAID binding protein; CSAID-binding protein; Csaids binding protein; CSBP 1; CSBP 2; CSBP; CSBP1; CSBP2; CSPB 1; CSPB1; Cytokine suppressive anti inflammatory drug binding protein; Cytokine suppressive anti-inflammatory drug-binding protein; EXIP; MAP kinase 14; MAP kinase MXI2; MAP kinase p38 alpha; MAPK 14; MAPK14; MAX interacting protein 2; MAX-interacting protein 2; Mitogen Activated Protein Kinase 14; Mitogen activated protein kinase p38 alpha; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase p38 alpha; MK14_HUMAN; Mxi 2; Mxi2; p38 ALPHA; p38; p38 MAP kinase; p38 MAPK; p38 mitogen activated protein kinase; p38alpha; p38alpha Exip; PRKM14; PRKM15; RK; SAPK 2A; SAPK2A; Stress Activated Protein Kinase 2A.	WB, IHC-P, FC, ICC/IF, ELISA	Human, Mouse
	Phospho-p38 alpha/MAPK14 (Thr180+Tyr182) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-p38 alpha/MAPK14 (Thr180+Tyr182).

HY-P85712

	*p38 alpha/MAPK14 Antibody (YA5404)* Mitogen-activated protein kinase 14; MAP kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding protein; CSAID-binding protein; CSBP; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MAP kinase p38 alpha; Stress-activated protein kinase 2a; SAPK2a;	WB, ICC/IF, ELISA	Human, Mouse, Rat
	p38 alpha/MAPK14 Antibody (YA5404) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p38 alpha/MAPK14.

HY-P86460

	*p38 alpha/MAPK14 Antibody (YA6152)* Mitogen-activated protein kinase 14; MAP kinase 14; MAPK 14; Cytokine suppressive anti-inflammatory drug-binding protein; CSAID-binding protein; CSBP; MAP kinase MXI2; MAX-interacting protein 2; Mitogen-activated protein kinase p38 alpha; MAP kinase p38 alpha; Stress-activated protein kinase 2a; SAPK2a;	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	p38 alpha/MAPK14 Antibody (YA6152) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p38 alpha/MAPK14.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-159799

p38α inhibitor 5		Alkynes
p38α inhibitor 5 (compound 1) is a PROTAC-type target protein ligand targeting p38 and can be used to synthesize NR-11c (HY-159798) .

HY-125387

TOP1210		Alkynes
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .

Cat. No.	Product Name		Classification

HY-RS08108

Mapk14 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Mapk14 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mapk14 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08107

MAPK14 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
MAPK14 Human Pre-designed siRNA Set A contains three designed siRNAs for MAPK14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS08109

Mapk14 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Mapk14 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mapk14 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks